恩瑞格疗效如何呢？

The chemical name of Deferasirox is 4-[3,5-bis(2-hydroxyphenyl)-1,2,4-triazol-1-yl]benzoic acid. It is an iron chelator product developed by the Swiss pharmaceutical company Novartis. It is the first oral iron anthelmintic approved by the US FDA for routine use. Enrig (Deferasirox) is approved for use in patients with iron accumulation caused by long-term blood transfusions (such as thalassemia or other rare anemias). , suitable for children over two years old and adults. How effective is Enrig (deferasirox)?

According to a retrospective study in Italy, 42.7% of patients achieved a hematological response and reduced the need for blood transfusions after receiving chelation therapy with DFO or Enrega (deferasirox). There may be a dynamic, bidirectional regulatory mechanism between erythropoiesis and iron overload. On the one hand, ineffective erythropoiesis can lead to increased intestinal iron absorption through reduced hepcidin secretion by the liver. On the other hand, chelation treatment of iron overload can improve erythropoiesis, increase hemoglobin levels, and reduce clinical blood transfusions.

In addition to reducing blood transfusions, iron chelation therapy has additional effects against tumor proliferation. Researchers added Enrig (deferasirox) to the bone marrow cell culture medium of patients with myelodysplastic syndrome (MDS) and found that the viability of MDS-derived progenitor cells was significantly reduced, and their cloning ability was also significantly inhibited. A study of 158 patients with serum ferritin >1000 ng/mL after hematopoietic stem cell transplantation found that 23 patients who received iron chelation therapy had a higher 5-year overall survival rate (59% vs. 34%, P = 0.008) and a lower risk of recurrence (18% vs. 41%, P = 0.012) than those who did not receive chelation therapy. It can be seen that iron chelating drugs can not only provide clinical benefits through iron removal, but also provide anti-tumor proliferation effects on certain myeloid leukemias.

The recommended starting daily dose is 20 mg/kg. For patients who receive monthly transfusions of more than 14 mL/kg of packed red blood cells (i.e., more than 4 units/month in adults) and who need to reduce excess iron exposure, a starting dose of 30 mg/kg/day may be considered. For patients who receive monthly transfusions of less than 7 mL/kg of packed red blood cells (i.e., less than 2 units/month in adults) and who need to maintain body iron balance, a starting dose of 10 mg/kg/day may be considered.